Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group

@article{Warren2005PhaseIT,
  title={Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group},
  author={K. Warren and R. Jakacki and B. Widemann and A. Aikin and M. Libucha and R. Packer and G. Vezina and G. Reaman and D. Shaw and M. Krailo and C. Osborne and J. Cehelsky and D. Caldwell and J. Stanwood and S. Steinberg and F. Balis},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2005},
  volume={58},
  pages={343-347}
}
  • K. Warren, R. Jakacki, +13 authors F. Balis
  • Published 2005
  • Medicine
  • Cancer Chemotherapy and Pharmacology
  • Backround: Lobradimil is a synthetic bradykinin analog that rapidly and transiently increases the permeability of the blood-brain barrier (BBB). The combination of lobradimil and carboplatin was studied in pediatric patients with primary brain tumors in a phase II trial, the primary endpoints of which were to estimate the response rate and time to disease progression. Patients and methods: Patients were stratified by histology into five cohorts: brainstem glioma, high-grade glioma, low-grade… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Lobradimil may increase the effectiveness of a chemotherapy drug… Expand
    ConditionsBrain and Central Nervous System Tumors
    InterventionDrug
    Diffuse intrinsic pontine glioma: poised for progress
    • 146
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 15 REFERENCES
    Carboplatin and recurrent childhood brain tumors.
    • 173
    Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors
    • 31
    Phase II Studies of RMP-7 and Carboplatin in the Treatment of Recurrent High Grade Glioma
    • 48
    Optimal two-stage designs for phase II clinical trials.
    • 2,993
    • PDF